Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.50 |
| ▸ | ACACB | O00763 | 4/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16997992 | 1.00 | PDE2A (0.50) | PDE2AACACBCTNNB1WNT3AOGA | |
| SCHEMBL29918974 | 1.00 | PDE2A (0.50) | PDE2AACACBCTNNB1WNT3AOGA | |
| SCHEMBL18237188 | 0.82 | PDE2A (0.61) | PDE2AACACBCTNNB1WNT3AOGA | |
| SCHEMBL31373869 | 0.81 | PDE2A (0.58) | PDE2AACACBCTNNB1WNT3A | |
| SCHEMBL29947811 | 0.76 | ALDH1A1 (0.64) | CTNNB1WNT3APOLB | |
| SCHEMBL8134776 | 0.76 | ALDH1A1 (0.54) | ACACBFAAHHPGDACACASLC1A3 | |
| SCHEMBL9046891 | 0.76 | ALDH1A1 (0.54) | ACACBFAAHHPGDACACASLC1A3 | |
| SCHEMBL8701763 | 0.76 | ALDH1A1 (0.54) | ACACBFAAHHPGDACACASLC1A3 | |
| SCHEMBL21793241 | 0.75 | ALDH1A1 (0.61) | ACACBFAAHPOLBACACASLC1A3 | |
| SCHEMBL27764271 | 0.75 | ALDH1A1 (0.61) | ACACBFAAHPOLBACACASLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259785-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | PDE2A 624/4885ACACB 1154/4885CTNNB1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.